Aldosterone and its Cardiovascular Effects

Textbook of Nephro-Endocrinology

Volumn , Issue , 2009, Pages 349-359

  Garg, Rajesh ^a   Adler, Gail K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882491395     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373870-7.00023-5     Document Type: Chapter

References (101)

1. Andronico G., Cottone S., Mangano M.T., et al. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 2001, 25:239-242.
2. Arima S., Kohagura K., Xu H.L., et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004, 43:352-357.
3. Bentley-Lewis R., Adler G.K., Perlstein T., et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007, 92:4472-4475.
4. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63:1791-1800.
5. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
6. Brown N.J., Kim K.S., Chen Y.Q., Blevins L.S., Nadeau J.H., Meranze S.G., Vaughan D.E. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000, 85:336-344.
7. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
8. Calle C., Campion J., Garcia-Arencibia M., Maestro B., Davila N. Transcriptional inhibition of the human insulin receptor gene by aldosterone. J Steroid Biochem Mol Biol 2003, 84:543-553.
9. Callera G.E., Touyz R.M., Tostes R.C., et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005, 45:773-779.
10. Campion J., Maestro B., Molero S., Davila N., Carranza M.C., Calle C. Aldosterone impairs insulin responsiveness in U-937 human promonocytic cells via the downregulation of its own receptor. Cell Biochem Funct 2002, 20:237-245.
11. Caprio M., Feve B., Claes A., Viengchareun S., Lombes M., Zennaro M.C. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21:2185-2194.
12. Catena C., Lapenna R., Baroselli S., et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006, 91:3457-3463.
13. Davies J.I., Band M., Morris A., Struthers A.D. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004, 47:1687-1694.
14. Dorrance A.M., Osborn H.L., Grekin R., Webb R.C. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 2001, 281:R944-R950.
15. Dorrance A.M., Rupp N.C., Nogueira E.F. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 2006, 47:590-595.
16. Dustan H.P. Mechanisms of hypertension associated with obesity. Ann Intern Med 1983, 98:860-864.
17. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc NatlAcad SciUSA 2003, 100:14211-14216.
18. Ehrhart-Bornstein M., Arakelyan K., Krug A.W., Scherbaum W.A., Bornstein S.R. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004, 30:865-870.
19. Engeli S., Bohnke J., Gorzelniak K., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356-362.
20. Enomoto S., Yoshiyama M., Omura T., et al. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. Heart 2005, 91:1595-1600.
21. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephol 2006, 1:940-951.
22. Farquharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597.
23. Farquharson C.A., Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond.) 2002, 103:425-431.
24. Feria I., Pichardo I., Juarez P., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003, 63:43-52.
25. Fiebeler A., Nussberger J., Shagdarsuren E., et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087-3094.
26. Funder J.W. Mineralocorticoid receptors: distribution and activation. Heart Fai Rev 2005, 10:15-22.
27. Ganie M.A., Khurana M.L., Eunice M., et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004, 89:2756-2762.
28. Gauer S., Hauser I.A., Obermuller N., Holzmann Y., Geiger H., Goppelt-Struebe M. Synergistic induction of osteopontin by aldosterone and inflammatory cytokines in mesangial cells. J Cell Biochem 2008, 103:615-623.
29. Goodfriend T.L., Egan B., Stepniakowski K., Ball D.L. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995, 25:30-36.
30. Goodfriend T.L., Egan B.M., Kelley D.E. Aldosterone in obesity. Endocr Res 1998, 24:789-796.
31. Grandi A.M., Imperiale D., Santillo R., et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002, 40:647-652.
32. Grossmann C., Benesic A., Krug A.W., et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 2005, 19:1697-1710.
33. Grossmann C., Krug A.W., Freudinger R., Mildenberger S., Voelker K., Gekle M. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab 2007, 292:E1790-E1800.
34. Grossmann C., Freudinger R., Mildenberger S., Husse B., Gekle M. EF-domains are sufficient for nongenomic mineralocorticoid receptor actions. J Biol Chem 2008, 283:7109-7116.
35. Guo C., Martinez-Vasquez D., Mendez G.P., et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006, 147:5363-5373.
36. Guo C., Ricchiuti V., Lian B.Q., et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, PPAR-gamma and pro-inflammatory adipokines. Circulation 2008, 117:2253-2261.
37. Haluzik M., Sindelka G., Widimsky J., Prazny M., Zelinka T., Skrha J. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens 2002, 16:41-45.
38. Han K.H., Kang Y.S., Han S.Y., et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006, 70:111-120.
39. Han S.Y., Kim C.H., Kim H.S., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006, 17:1362-1372.
40. Hansen P.R., Rieneck K., Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett 2004, 91:87-91.
41. Hiramatsu K., Yamada T., Ichikawa K., Izumiyama T., Nagata H. Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc 1981, 29:25-30.
42. Hitomi H., Kiyomoto H., Nishiyama A., et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007, 50:750-755.
43. Ishizawa K., Izawa Y., Ito H., et al. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension 2005, 46:1046-1052.
44. Iwashima F., Yoshimoto T., Minami I., Sakurada M., Hirono Y., Hirata Y. Aldosterone induces superoxide generation via rac1 activation in endothelial cells. Endocrinology 2008, 149:1009-1014.
45. Izawa H., Murohara T., Nagata K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005, 112:2940-2945.
46. Jaffe I.Z., Mendelsohn M.E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005, 96:643-650.
47. Joffe H.V., Adler G.K. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005, 10:31-37.
48. Joffe H.V., Kwong R.Y., Gerhard-Herman M.D., Rice C., Feldman K., Adler G.K. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007, 92:2552-2558.
49. Kang Y.M., Zhang Z.H., Johnson R.F., et al. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ Res 2006, 99:758-766.
50. Keidar S., Hayek T., Kaplan M., et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003, 41:955-963.
51. Keidar S., Kaplan M., Pavlotzky E., et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213-2220.
52. Kraus D., Jager J., Meier B., Fasshauer M., Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005, 37:455-459.
53. Kuster G.M., Kotlyar E., Rude M.K., et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005, 111:420-427.
54. Leopold J.A., Dam A., Maron B.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007, 13:189-197.
55. Liu S.L., Schmuck S., Chorazcyzewski J.Z., Gros R., Feldman R.D. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003, 108:2400-2406.
56. Luther J.M., Gainer J.V., Murphey L.J., et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006, 48:1050-1057.
57. Martinez D.V., Rocha R., Matsumura M., et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002, 39:614-618.
58. 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 2005, 146:973-980.
59. Min L.J., Mogi M., Li J.M., Iwanami J., Iwai M., Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005, 97:434-442.
60. Miric G., Dallemagne C., Endre Z., Margolin S., Taylor S.M., Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001, 133:687-694.
61. Moghetti P., Tosi F., Castello R., et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996, 81:952-960.
62. Nagata D., Takahashi M., Sawai K., et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006, 48:165-171.
63. New England Research Institutes and National Heart Lung and Blood Institute of the National Institutes of Health. (2008). TOPCAT Study. http://www.topcatstudy.com/.
64. Nietlispach F., Julius B., Schindler R., et al. Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 2007, 50:82-88.
65. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
66. Oestreicher E.M., Martinez-Vasquez D., Stone J.R., et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 2003, 108:2517-2523.
67. Ouzan J., Perault C., Lincoff A.M., Carre E., Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333-339.
68. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
69. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831-1838.
70. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
71. Quinkler M., Zehnder D., Eardley K.S., et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005, 112:1435-1443.
72. Rachmani R., Slavachevsky I., Amit M., et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004, 21:471-475.
73. Rickard A.J., Funder J.W., Fuller P.J., Young M.J. The role of the glucocorticoid receptor in mineralocorticoid/salt-mediated cardiac fibrosis. Endocrinology 2006, 147:5901-5906.
74. Rocchini A.P., Katch V.L., Grekin R., Moorehead C., Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986, 57:613-618.
75. Rocha R., Chander P.N., Khanna K., Zuckerman A., Stier C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
76. Rocha R., Stier C.T., Kifor I., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871-3878.
77. Rocha R., Martin-Berger C.L., Yang P., Scherrer R., Delyani J., McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828-4836.
78. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802-H1810.
79. Rossi G.P., Sacchetto A., Visentin P., et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039-1045.
80. Rossi G.P., Sacchetto A., Pavan E., et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997, 95:1471-1478.
81. Rossing K., Schjoedt K.J., Smidt U.M., Boomsma F., Parving H.H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005, 28:2106-2112.
82. Sanz-Rosa D., Cediel E., de las Heras N., et al. Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. J Hypertens 2005, 23:1167-1172.
83. Sato A., Hayashi K., Naruse M., Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.
84. Schmidt B.M., Oehmer S., Delles C., et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003, 42:156-160.
85. Shibata S., Nagase M., Yoshida S., Kawachi H., Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49:355-364.
86. Siragy H.M., Xue C. Local renal aldosterone production induces inflammation and matrix formation in Kidneys of diabetic rats. Exp Physiol 2008, 93:817-824.
87. Sugiyama T., Yoshimoto T., Tsuchiya K., et al. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005, 146:3900-3906.
88. Trachtman H., Weiser A.C., Valderrama E., Morgado M., Palmer L.S. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 2004, 172:1590-1594.
89. Tuck M.L., Sowers J., Dornfeld L., Kledzik G., Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981, 304:930-933.
90. van den Meiracker A.H., Baggen R.G., Pauli S., et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006, 24:2285-2292.
91. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689-1697.
92. White W.B., Carr A.A., Krause S., Jordan R., Roniker B., Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003, 92:38-42.
93. White W.B., Duprez D., St Hillaire R., et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41:1021-1026.
94. Williams G.H., Burgess E., Kolloch R.E., et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004, 93:990-996.
95. Young M., Fullerton M., Dilley R., Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
96. Young M., Head G., Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995, 269:E657-E662.
97. Young M.J., Moussa L., Dilley R., Funder J.W. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 2003, 144:1121-1125.
98. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation 2000, 102:2700-2706.
99. Zulian E., Sartorato P., Benedini S., et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005, 28:49-53.
100. Goodfriend T.L., Egan B.M., Kelley D.E. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60:401-405.
101. Goodfriend T.L., Kelley D.E., Goodpaster B.H., Winters S.J. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999, 7:355-362.